199
Participants
Start Date
March 11, 2014
Primary Completion Date
May 3, 2018
Study Completion Date
October 28, 2020
Nab-Paclitaxel
Paclitaxel
Prince of Wales Hospital, Sydney
Concord Cancer Centre, Sydney
Liverpool Hospital, Sydney
Port Macquarie Base Hospital, Port Macquarie
Western Hospital (renamed to Footscray Hospital), St Albans
St Vincents Hospital Melbourne, Fitzroy
Epworth Healthcare Freemasons Hospital, Richmond
Box Hill Hospital, Box Hill
Frankston Hospital, Frankston
Peninsula Oncology Centre, Frankston
University Hospital Geelong, Geelong
Border Medical Oncology (Murray Valley Private Hospital), Wodonga
Nambour General Hospital, Nambour
Townsville Hospital, Douglas
Ashford Cancer Care Research, Kurralta Park
Flinders Medical Centre, Bedford Park
Royal Perth Hospital (renamed to Fiona Stanley Hospital), Perth
Royal Hobart Hospital, Hobart
Tom Baker Cancer Centre, Calgary
Cross Cancer Institute, Edmonton
BCCA - Vancouver Cancer Centre, Vancouver
QEII Health Sciences Centre, Halifax
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
Cancer Centre of Southeastern Ontario at Kingston, Kingston
London Regional Cancer Program, London
Stronach Regional Health Centre at Southlake, Newmarket
Lakeridge Health Oshawa, Oshawa
Ottawa Hospital Research Institute, Ottawa
University Health Network, Toronto
Hopital Charles LeMoyne, Greenfield Park
CHUM - Hopital Notre-Dame, Montreal
The Jewish General Hospital, Montreal
The Research Institute of the McGill University, Montreal
Centre hospitalier universitaire de Sherbrooke, Sherbrooke
Centre hospitalier regional de Trois-Rivieres, Trois-Rivières
Allan Blair Cancer Centre, Regina
Saskatoon Cancer Centre, Saskatoon
Collaborators (1)
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
OTHER
Celgene
INDUSTRY
Canadian Cancer Trials Group
NETWORK